Pharmaceutical pricing and reimbursement information (PPRI): evolution and impact of a policy network over two decades.

IF 2.6 Q1 HEALTH POLICY & SERVICES
Journal of Pharmaceutical Policy and Practice Pub Date : 2026-05-20 eCollection Date: 2026-01-01 DOI:10.1080/20523211.2026.2670697
Sabine Vogler, Friederike Windisch, Verena Knoll, Katharina Kieslich
{"title":"Pharmaceutical pricing and reimbursement information (PPRI): evolution and impact of a policy network over two decades.","authors":"Sabine Vogler, Friederike Windisch, Verena Knoll, Katharina Kieslich","doi":"10.1080/20523211.2026.2670697","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>In 2005, the Pharmaceutical Pricing and Reimbursement Information (PPRI) network of public authorities was established to offer a platform for information exchange among authorities responsible for pharmaceutical pricing and reimbursement. The article reviews the evolution of PPRI over its twenty years of existence and aims to identify its contributions to policymakers and the research community as well as areas for future development.</p><p><strong>Methods: </strong>Based on a framework of structure, process and outcome indicators, adapted from the Donabedian Model, the article examines developments regarding membership in terms of geographic and thematic scope, governance, procedures for intra-network exchange of information as well as stakeholder engagement, and outcomes in terms of scientific output and spin-off activities. The review was informed by grey and peer-reviewed literature as well as unpublished information within the PPRI network.</p><p><strong>Results: </strong>The PPRI network has evolved from a European group into a global network, comprising approximately 80 public authorities in pharmaceutical pricing and reimbursement from 50 countries. Its thematic focus remains pricing and reimbursement policies, and additionally, the PPRI network addressed several related topics. In 2018, a sub-group on medical devices (PPRI MD) was established. PPRI mainly serves its members by facilitating informed discussion at face-to-face and online meetings, and through internal queries on timely and policy-related topics. PPRI-sourced data has been published, including country information such as PPRI Pharma Profiles and Briefs, and scientific studies based on cross-country analyses. PPRI conferences offer an opportunity for disseminating scientific output and engaging with stakeholders.</p><p><strong>Conclusion: </strong>PPRI is a network that has proven its value to policymakers by fostering information exchange as well as by producing reliable and relevant evidence. Success factors identified include a robust governance structure with clear responsibilities, a dedicated Secretariat as a coordinating function and the safe-space character of the network for its members.</p>","PeriodicalId":16740,"journal":{"name":"Journal of Pharmaceutical Policy and Practice","volume":"19 1","pages":"2670697"},"PeriodicalIF":2.6000,"publicationDate":"2026-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13192097/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmaceutical Policy and Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/20523211.2026.2670697","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"HEALTH POLICY & SERVICES","Score":null,"Total":0}
引用次数: 0

Abstract

Background: In 2005, the Pharmaceutical Pricing and Reimbursement Information (PPRI) network of public authorities was established to offer a platform for information exchange among authorities responsible for pharmaceutical pricing and reimbursement. The article reviews the evolution of PPRI over its twenty years of existence and aims to identify its contributions to policymakers and the research community as well as areas for future development.

Methods: Based on a framework of structure, process and outcome indicators, adapted from the Donabedian Model, the article examines developments regarding membership in terms of geographic and thematic scope, governance, procedures for intra-network exchange of information as well as stakeholder engagement, and outcomes in terms of scientific output and spin-off activities. The review was informed by grey and peer-reviewed literature as well as unpublished information within the PPRI network.

Results: The PPRI network has evolved from a European group into a global network, comprising approximately 80 public authorities in pharmaceutical pricing and reimbursement from 50 countries. Its thematic focus remains pricing and reimbursement policies, and additionally, the PPRI network addressed several related topics. In 2018, a sub-group on medical devices (PPRI MD) was established. PPRI mainly serves its members by facilitating informed discussion at face-to-face and online meetings, and through internal queries on timely and policy-related topics. PPRI-sourced data has been published, including country information such as PPRI Pharma Profiles and Briefs, and scientific studies based on cross-country analyses. PPRI conferences offer an opportunity for disseminating scientific output and engaging with stakeholders.

Conclusion: PPRI is a network that has proven its value to policymakers by fostering information exchange as well as by producing reliable and relevant evidence. Success factors identified include a robust governance structure with clear responsibilities, a dedicated Secretariat as a coordinating function and the safe-space character of the network for its members.

药品定价和报销信息(PPRI): 20年来政策网络的演变和影响。
背景:2005年,政府主管部门建立了药品定价与报销信息(PPRI)网络,为负责药品定价与报销的主管部门之间提供信息交流平台。这篇文章回顾了PPRI 20年来的发展历程,旨在确定它对决策者和研究界的贡献以及未来发展的领域。方法:基于改编自Donabedian模型的结构、过程和结果指标框架,本文从地理和专题范围、治理、网络内信息交换程序以及利益相关者参与以及科学产出和附带活动方面的成果等方面考察了成员关系的发展。该审查是由灰色和同行评议的文献以及PPRI网络内未发表的信息提供的。结果:PPRI网络已经从一个欧洲集团发展成为一个全球网络,包括来自50个国家的药品定价和报销方面的大约80个公共机构。其主题重点仍然是定价和报销政策,此外,方案研究所网络还讨论了若干相关主题。2018年成立医疗器械分组(PPRI MD)。PPRI主要通过促进面对面和在线会议的知情讨论,以及及时和政策相关主题的内部查询,为其成员提供服务。PPRI提供的数据已经公布,包括国家信息,如PPRI制药概况和简报,以及基于跨国分析的科学研究。PPRI会议为传播科学成果和与利益攸关方接触提供了机会。结论:PPRI是一个网络,通过促进信息交流以及提供可靠和相关的证据,证明了其对决策者的价值。所确定的成功因素包括:职责明确的强有力的管理结构,作为协调职能的专门秘书处,以及网络为其成员提供安全空间的特点。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Pharmaceutical Policy and Practice
Journal of Pharmaceutical Policy and Practice Health Professions-Pharmacy
CiteScore
4.70
自引率
9.50%
发文量
81
审稿时长
14 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书